Adenovirus expertise

Building on its world leading position in lentiviral vectors, Oxford Biomedica has demonstrated the versatility of its platform by undertaking the large-scale commercial manufacture of AstraZeneca's adenovirus vector-based COVID-19 vaccine at the Company’s Oxbox facility.

Oxford Biomedica has an 18-month supply agreement under a three-year Master Supply and Development Agreement with AstraZeneca for large-scale commercial manufacture of the adenovirus vector-based COVID-19 vaccine, announced in September 2020.

This follows on from an initial one year clinical and commercial supply agreement with AstraZeneca.